Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients
Status:
Completed
Trial end date:
2016-05-18
Target enrollment:
Participant gender:
Summary
This Phase 1b trial will assess the dose-related safety and PK profile of different doses of
NVR 3-778 in patients with chronic hepatitis B. Additionally,changes in patients' serum HBV
DNA levels and other virologic efficacy parameters will be assessed.